Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions

This article was originally published in The Pink Sheet Daily

Executive Summary

In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.

You may also be interested in...



ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.

Rethinking Oncology Development: Master Protocols May Shorten Time To Approval

Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”

Master Protocol For Metastatic Breast Cancer Needs To Adapt To Rational Combinations

Beyond saving money and creating efficiencies, stakeholders want a master trial to foster true innovation in metastatic breast cancer treatment. Various ways to deal with dosing and other challenges in testing rational combinations of different interventions were discussed at recent workshop.

Related Content

Topics

UsernamePublicRestriction

Register

PS075834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel